Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NELSON P KOPYT

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1104802891
CMS profile
276589
Location
ALLENTOWN, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$125,014.63

165 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 4 of 4; records 151–165 of 165 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NELSON P KOPYT

NPI 1104802891 · CMS profile ID 276589

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

ALLENTOWN, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–165 of 165 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104802891?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NELSON P KOPYT, NPI 1104802891, CMS profile ID 276589. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–165 of 165 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104802891?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). NELSON P KOPYT, NPI 1104802891, CMS profile ID 276589. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–165 of 165 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104802891?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
NELSON P KOPYT, NPI 1104802891, CMS profile ID 276589, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–165 of 165 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1104802891?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

165 matching records · $125,014.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 165 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–165 of 165.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $1,710.0002/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186816715 CMS
Lilly USA, LLC $1,140.0002/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186828546 CMS
Lilly USA, LLC $1,140.0002/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186828548 CMS
Lilly USA, LLC $1,140.0002/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186795741 CMS
Amgen Inc. $47.5702/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228522184 CMS
Lilly USA, LLC $1,140.0002/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186803171 CMS
Lilly USA, LLC $1,140.0002/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186795739 CMS
Lilly USA, LLC $28.7102/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186803175 CMS
Novartis Pharmaceuticals Corporation $33.7801/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200360796 CMS
Alkermes, Inc. $124.7401/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222544814 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.9201/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225611024 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.2201/28/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1225611026 CMS
Lilly USA, LLC $1,140.0001/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186772710 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $32.8601/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222785040 CMS
Ardelyx, Inc. $700.0001/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1247860242 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $218,362.56 336
PY2020 $96,947.66 155
PY2021 $148,088.30 148
PY2022 $170,855.71 201
PY2023 $95,166.31 118
PY2024 $95,004.42 143
PY2025 $125,014.63 165

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,352.91 16
PY2025 Principal investigator $110,537.99 19
PY2024 Recipient $1,001.42 1
PY2024 Principal investigator $106,433.15 20
PY2023 Principal investigator $192,291.25 27
PY2022 Principal investigator $72,410.65 16
PY2021 Principal investigator $112,042.48 35
PY2020 Recipient $6,528.33 2
PY2020 Principal investigator $207,891.14 62
PY2019 Recipient $1,392.89 16
PY2019 Principal investigator $314,581.43 93

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,813.75 12/04/2025 Non-covered Recipient Entity
NORTHEAST CLINICAL RESEARCH CENTER
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202528226
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,350.56 11/24/2025 Non-covered Recipient Entity
Northeast Clinical Research Center
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225415420
Principal investigator 1 ABBVIE INC. $5,890.05 11/05/2025 Non-covered Recipient Entity
NORTHEAST CLINICAL RESEARCH CENTER
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202523103
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,331.77 10/28/2025 Non-covered Recipient Entity
Northeast Clinical Research Center
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225414096
Principal investigator 1 ABBVIE INC. $1,811.70 10/09/2025 Non-covered Recipient Entity
NORTHEAST CLINICAL RESEARCH CENTER
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202515935
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,331.77 09/25/2025 Non-covered Recipient Entity
Northeast Clinical Research Center
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225414884
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $125.00 08/22/2025 Non-covered Recipient Entity
Northeast Clinical Research Center
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225413504
Recipient ABBVIE INC. $52.88 08/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202399430
Recipient ABBVIE INC. $401.56 08/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202399435
Recipient ABBVIE INC. $56.00 08/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202399439
Recipient ABBVIE INC. $11.58 08/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202399442
Recipient ABBVIE INC. $5.45 08/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202399446
Recipient ABBVIE INC. $7.55 08/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202399450
Recipient ABBVIE INC. $5.00 08/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202399454
Recipient ABBVIE INC. $124.99 08/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202399401
Recipient ABBVIE INC. $15.00 08/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202399405
Recipient ABBVIE INC. $215.46 08/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202399408
Recipient ABBVIE INC. $5.00 08/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202399412
Recipient ABBVIE INC. $36.15 08/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202399416
Recipient ABBVIE INC. $93.10 08/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202399418
Recipient ABBVIE INC. $11.58 08/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202399422
Recipient ABBVIE INC. $11.61 08/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202399426
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,331.77 07/24/2025 Non-covered Recipient Entity
Northeast Clinical Research Center
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225413146
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $5,014.67 05/30/2025 Non-covered Recipient Entity
Northeast Clinical Research Center
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225412700
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,268.28 05/12/2025 Non-covered Recipient Entity
NORTHEAST CLINICAL RESEARCH CENTER, LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function No dispute reported 06/30/2026 1190301799
Principal investigator 1 ABBVIE INC. $12,476.00 05/07/2025 Non-covered Recipient Entity
NORTHEAST CLINICAL RESEARCH CENTER
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202482405
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,555.52 03/27/2025 Non-covered Recipient Entity
Northeast Clinical Research Center
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1225405562
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,331.77 03/06/2025 Non-covered Recipient Entity
Northeast Clinical Research Center
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1225402785
Principal investigator 1 Eli Lilly and Company $183.93 03/03/2025 Non-covered Recipient Entity
NORTHEAST CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187885318
Principal investigator 1 Eli Lilly and Company $245.57 02/17/2025 Non-covered Recipient Entity
NORTHWEST CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187890130
Principal investigator 1 Eli Lilly and Company $34,665.00 02/11/2025 Non-covered Recipient Entity
NORTHEAST CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187887674
Recipient ABBVIE INC. $3,300.00 01/31/2025 Covered Recipient Physician PAPP-A Ph2 SCLC ADPKD No dispute reported 06/30/2026 1202399397
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,331.77 01/28/2025 Non-covered Recipient Entity
Northeast Clinical Research Center
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1225403177
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,683.98 01/17/2025 Non-covered Recipient Entity
NORTHEAST CLINICAL RESEARCH CENTER, LLC
A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension No dispute reported 06/30/2026 1185538529
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,795.13 01/08/2025 Non-covered Recipient Entity
NORTHEAST CLINICAL RESEARCH CENTER, LLC
TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal No dispute reported 06/30/2026 1185538527